Wed, December 20, 2023

Andreas Argyrides Maintained (ASND) at Buy with Increased Target to $202 on, Dec 20th, 2023

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-202-on-dec-20th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Andreas Argyrides of Wedbush, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $200 to $202 on, Dec 20th, 2023.

Andreas has made no other calls on ASND in the last 4 months.



There are 2 other peers that have a rating on ASND. Out of the 2 peers that are also analyzing ASND, 1 agrees with Andreas's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $116 on, Thursday, November 9th, 2023


This is the rating of the analyst that currently disagrees with Andreas


  • Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $149 on, Tuesday, December 19th, 2023